- Details
- Description
Packaging Size:
30 tablets (1 × 30)
Strength:
40 mg
Composition:
Gilteritinib fumarate equivalent to Gilteritinib 40 mg per film-coated tablet
Treatment:
Oral targeted anticancer medicine used for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib is a FLT3 inhibitor that blocks abnormal FLT3 signaling in leukemia cells.
Form:
Film-coated tablet
Brand:
Gilternib 40 mg
Quantity Unit:
Tablet
Manufacturer:
Everest Pharmaceuticals Ltd., Bangladesh
Gilternib 40 mg is an oral targeted anticancer medicine manufactured by Everest Pharmaceuticals Ltd., Bangladesh. Each film-coated tablet contains Gilteritinib 40 mg as gilteritinib fumarate. Gilteritinib is a selective tyrosine kinase inhibitor that targets FLT3, a protein involved in the growth and survival of certain leukemia cells. It is indicated for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. The medicine is generally prescribed under specialist supervision, with monitoring required during treatment because of potential adverse effects including QT interval prolongation and other serious reactions
